Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 174,819

Document Document Title
WO/2018/165766A1
A method for the purification of albumin from plasma is described. The method comprises (a) contacting the plasma with sodium caprylate (NaCP) at an amount dependent on total protein concentration and the ratio of NaCP to total protein i...  
WO/2018/166807A1
The invention generally relates to pharmaceuticals and/or nutraceuticals. More particularly, the invention provides compositions of collagen-based peptides and specific digestive tract microbes useful for supporting or promoting joint, s...  
WO/2018/168777A1
Provided are a method whereby cystic fibrosis can be prevented or treated by inhibiting a mechanism in which ΔF508 CFTR expressed in the plasma membrane is ubiquitinated by a plasma membrane quality control system and then subjected to ...  
WO/2018/168997A1
The purpose of the present invention is to provide an oral composition that possesses an excellent teeth remineralization promoting effect and that is capable of effectively promoting teeth remineralization even when retained in the oral...  
WO/2018/166468A1
Disclosed are an IgG-like long-acting immune fusion protein and the use thereof. The IgG-like long-acting immune fusion protein consists of an effector molecule and a constant region of an IgG antibody, and the effector molecule is linke...  
WO/2018/169090A1
Provided is an agent for suppressing or reducing photoreception sensitivity containing a substance that inhibits or suppresses ubiquitination, such as an agent for suppressing or reducing photoreception sensitivity that protects the reti...  
WO/2018/169954A1
The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle...  
WO/2018/169385A1
The present invention relates to a peptide composition capable of binding with major histocompatibility complex class I molecules to induce an anti-cancer immune response in a subject. Particularly, the peptide composition comprises at l...  
WO/2018/165764A1
Provided are peptides that are derived from probiotic bacteria that may be useful for preventing and/or treating enteric infections or non-enteric infections in a subject. The peptides may also find use for reducing the virulence of ente...  
WO/2018/167469A1
The present invention relates to modified proteins e.g. oxygen-carrying proteins, with improved or enhanced, in comparison to a reference protein, reduction of a metal ion associated with the modified protein. The present invention also ...  
WO/2018/167151A1
The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to...  
WO/2018/168779A1
The purpose of the present invention is to provide a biomarker for chronic obstructive pulmonary diseases, and a method for using the biomarker. The present invention involves an extracellular-vesicle protein group (A) which is in a body...  
WO/2018/169811A1
Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammator...  
WO/2018/170152A1
The disclosure provides, in part, compositions comprising mature recombinant mature Complement Factor I (CFI) protein and methods of making and using those compositions.  
WO/2018/170015A1
Described herein are methods of avoiding an immune response in a subject being administered a regimen requiring Cas9 in order to optimize and broaden the application of CRIPSR based therapeutics comprising administering immune orthogonal...  
WO/2018/170273A1
Polypeptides that bind to viral hemagglotinin are disclosed and methods for their use in treating or limiting influenza infection, and diagnosing influenza infection.  
WO/2018/166632A1
The invention relates to the field of storage of tissues, such as transplantable material, or allograft storage, and more specifically to the field of both short- and long-term tissues storage and preservation. Preferably the tissues are...  
WO/2018/166589A1
The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to...  
WO/2018/167194A1
The present invention relates to novel peptide compounds which are effective as melanocortin 4 receptor agonists, to the use of the compounds in medicine, to methods of treatment comprising administration of the compounds to patients in ...  
WO/2018/169314A1
The present invention relates to a hydrogel patch, a preparation method therefor, and a composition comprising the same for treatment of spinal cord injury. A hydrogel patch according to one embodiment has the effect of being able to tre...  
WO/2018/170480A1
Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent compl...  
WO/2018/169442A1
This invention relates to medical biotechnology, medicine, traumatology, orthopedics, dentistry, and orthodontics. A method is proposed for producing a biological matrix intended for the repairing of bone tissue defects; said method may ...  
WO/2018/169900A1
The present invention provides new and improved methods for performing in situ transcriptomics from rare "cells of interest" present in complex multicellular environments.These methods involve expressing a recombinant cytosine deaminase ...  
WO/2018/170205A1
Methods, compositions and kits are provided that include microneedles coated with or formed of antigens to which immune tolerance is desired. Use of the microneedles is demonstrated using glatiramer acetate and animal models of multiple ...  
WO/2018/167105A1
The invention relates to a fusion protein containing a selective cell death-inducing enzyme system for use in the therapy and/or treatment of cancer and tumors in humans and animals, a process, and its use.  
WO/2018/170324A1
Aggregated Tau protein is associated with over 20 neurological disorders including Alzheimer's disease. Previous work has shown that Tau's sequence segments VQIINK and VQIVYK drive its aggregation, and that inhibitors based on the struct...  
WO/2018/166119A1
Disclosed are a polypeptide targeted at promoting EGFR protein degradation, or a derivative of the polypeptide and the use thereof in the preparation of a drug for treating tumours. The amino acid sequence of the polypeptide is as shown ...  
WO/2018/169296A1
The present invention relates to medical devices in the form of mucoadhesive films for the release of live lactic bacteria and bifidobacteria (probiotics) and/or for the release and maintenance of their pharmacologically useful enzyme ac...  
WO/2018/169158A1
The present invention relates to a composition, for preventing or treating degenerative arthritis, comprising as an active ingredient dual Ig domain containing cell adhesion molecule (DICAM) protein or nucleic acid molecules coding DICAM...  
WO/2018/167287A1
The invention relates to the field of treatment or prevention of obesity-related disorders, atherosclerosis or a coagulation disorder. In particular, the present invention relates to the use of an activator of IFNλ receptor for the trea...  
WO/2018/170390A1
Provided herein are methods and compositions for dynamically controlling and targeting multiple arms of the immune system. Some aspects provide mesenchymal stem cells (MSCs) engineered to produce multiple effector molecules. In some inst...  
WO/2018/167295A1
Disclosed are compounds represented by the following general formula (I): Cyclo-(Arg-Gly-Asp-X1-X2-X3-X4-X5) (I) wherein the variables groups X1 to X5 have the following meanings X1: Leu, Ile, Nle, Val, Tyr, Phe; X2: D-amino acid such as...  
WO/2018/170172A1
The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more...  
WO/2018/169934A1
Aco-drug is represented by Formula (I) or Formula (II), R-X-NH-CO-CO-OR1 (I) R-X-CO-O-CH2-CO-OR1 (II) where R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and OR1 is the resid...  
WO/2018/170299A1
Disclosed herein are polypeptides, compositions, and methods for the treatment and/or prevention of microbial infections. In certain aspects, the disclosure provides a polypeptide derived from a bacterial RNA polymerase cofactor (e.g., a...  
WO/2018/170021A1
Provided herein are immunomodulatory proteins comprising variant PD-Ll and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Composi...  
WO/2018/169804A1
A neuromuscular toxin is for use in treating abnormalities of the first metatarsophalangeal joint of the foot of a mammal by administering an amount of neuromuscular toxin effective to treat the abnormalities via intramuscular injection ...  
WO/2018/170134A1
Disclosed are methods and compositions related to immunoconjugates. Particularly disclosed are immunoconjugates that comprise the Fc portion of IgG3 as well as Factor VII light chain or Factor VII. Also disclosed is an immunoconjugate pr...  
WO/2018/170023A1
Provided herein are immunomodulatory proteins comprising variant PD-L2 and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Composi...  
WO/2018/170288A1
Methods and compounds for conferring site-specific or local immune privilege.  
WO/2018/165933A1
Polypeptide for regulating saccharometabolism and uses thereof in the preparation of drugs for treating diseases related to saccharometabolism. The polypeptide can reduce blood sugar, can promote insulin secretion, can be used in the pre...  
WO/2018/165707A1
The present invention relates to improved phosphopeptide stabilised amorphous calcium phosphate and/or amorphous calcium fluoride phosphate complexes and compositions containing those complexes. Methods of making the complexes of the inv...  
WO/2018/165936A1
Polypeptide for regulating energy metabolism and uses thereof in the preparation of drugs for treating diseases related to abnormal energy metabolism. The polypeptide can reduce fat absorption, can reduce fat accumulation in a liver and ...  
WO/2018/166461A1
Provided is a fusion protein containing GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with its analogues or variants and, the Fc portion, which can be derived from IgG4, can i...  
WO/2018/170178A1
Methods of breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of a polypeptide that has one or more modified HMG-box 1 domains to a sub...  
WO/2018/169282A2
The present invention relates to a pharmaceutical composition containing ATPase inhibitor factor 1 (ATPIF1) as an active ingredient for the prevention or treatment of diabetes or diabetic complications, and to a pharmaceutical compositio...  
WO/2018/165765A1
Provided are peptides that are derived from probiotic bacteria that have use for preventing and/or treating non-enteric infections in a subject. The peptides derived from the probiotic bacteria also have use for reducing the virulence of...  
WO/2018/161135A1
The present invention describes i) the construction of synthetic genes for components of a recombinant fibrin glue: fibrinogen A, fibrinogen B, fibrinogen G, factor XIIIA, prothrombin, ecarin and ERp57; ii) the expression of said genes i...  
WO/2018/164712A1
The present invention is a DNA expression vector comprising: a toxP; a mutant toxO that blocks Fe-mediated regulation of gene expression; and a DNA sequence encoding a protein, wherein the toxP and the mutant toxO regulate expression of ...  
WO/2018/165417A1
The present invention provides methods for determining bone growth velocity comprising: (a) measuring an amount of a collagen X marker in a sample obtained from a subject in need thereof; and (b) comparing the amount of collagen X marker...  

Matches 1 - 50 out of 174,819